34,328 Edwards Lifesciences Corporation $EW Shares Sold by Ninety One North America Inc.

Posted by Brenda Bartman on Oct 15th, 2026

Ninety One North America Inc. lessened its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW – Free Report) by 5.6% during the third quarter, HoldingsChannel.com reports. The firm owned 582,170 shares of the medical research company’s stock after selling 34,328 shares during the quarter. Edwards Lifesciences makes up about 2.5% of Ninety One North America Inc.’s holdings, making the stock its 11th biggest holding. Ninety One North America Inc.’s holdings in Edwards Lifesciences were worth $50,253,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the business. Rehmann Capital Advisory Group grew its position in Edwards Lifesciences by 2.1% in the 4th quarter. Rehmann Capital Advisory Group now owns 6,399 shares of the medical research company’s stock valued at $546,000 after acquiring an additional 130 shares during the last quarter. NorthRock Partners LLC raised its holdings in shares of Edwards Lifesciences by 1.0% in the 2nd quarter. NorthRock Partners LLC now owns 16,191 shares of the medical research company’s stock valued at $1,465,000 after purchasing an additional 153 shares in the last quarter. Elevation Wealth Partners LLC boosted its position in Edwards Lifesciences by 24.8% during the 3rd quarter. Elevation Wealth Partners LLC now owns 779 shares of the medical research company’s stock valued at $67,000 after acquiring an additional 155 shares in the last quarter. Plan A Wealth LLC boosted its position in Edwards Lifesciences by 3.0% during the third quarter. Plan A Wealth LLC now owns 5,460 shares of the medical research company’s stock valued at $471,000 after purchasing an additional 158 shares in the last quarter. Finally, Premier Path Wealth Partners LLC boosted its holdings in shares of Edwards Lifesciences by 4.4% in the 1st quarter. Premier Path Wealth Partners LLC now owns 3,880 shares of the medical research company’s stock valued at $311,000 after buying an additional 162 shares in the last quarter. 79.46% of the stock is owned by institutional investors.

Insider Activity

In related news, SVP Andrew M. Dahl sold 544 shares of the company’s stock in a transaction dated Monday, August 31st. The shares were sold at an average price of $91.06, for a total value of $49,536.64. Following the completion of the sale, the senior vice president owned 14,868 shares of the company’s stock, valued at approximately $1,353,880.08. This represents a 3.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, VP Daniel Lippis sold 619 shares of the company’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total transaction of $56,966.57. Following the completion of the sale, the vice president directly owned 40,034 shares of the company’s stock, valued at $3,684,329.02. This represents a 1.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 5,045 shares of company stock valued at $451,596. 0.31% of the stock is currently owned by insiders.

Edwards Lifesciences Trading Up 0.1%

NYSE EW traded up $0.11 on Thursday, reaching $86.56. 1,261,235 shares of the company were exchanged, compared to its average volume of 4,490,733. The business’s fifty day moving average price is $88.53 and its 200 day moving average price is $86.27. The stock has a market capitalization of $49.84 billion, a P/E ratio of 49.73, a price-to-earnings-growth ratio of 2.23 and a beta of 0.87. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a fifty-two week low of $72.42 and a fifty-two week high of $96.29.

Edwards Lifesciences (NYSE:EW – Get Free Report) last issued its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%. The company had revenue of $1.74 billion during the quarter, compared to analysts’ expectations of $1.70 billion. During the same period in the prior year, the business earned $0.67 EPS. The firm’s quarterly revenue was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Analysts forecast that Edwards Lifesciences Corporation will post 3.00 earnings per share for the current year.

Wall Street Analysts Forecast Growth

EW has been the topic of several research analyst reports. UBS Group restated a “buy” rating on shares of Edwards Lifesciences in a research note on Thursday, October 8th. TD Cowen reiterated a “buy” rating on shares of Edwards Lifesciences in a research note on Tuesday, July 21st. Mizuho raised their target price on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “outperform” rating in a report on Wednesday, July 15th. JPMorgan Chase & Co. lifted their price objective on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the company an “overweight” rating in a report on Friday, July 24th. Finally, Leerink Partners upgraded Edwards Lifesciences from a “market perform” rating to an “outperform” rating and boosted their price objective for the company from $87.00 to $101.00 in a research report on Friday, July 24th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $100.27.

Check Out Our Latest Report on Edwards Lifesciences

Edwards Lifesciences Profile

(Free Report)

Edwards Lifesciences Corporation is a medical technology company focused on therapies for structural heart disease and other cardiovascular conditions. The company develops and manufactures heart valve replacement and repair technologies, including transcatheter aortic valve replacement systems, surgical heart valves, transcatheter mitral and tricuspid therapies, and related delivery systems and accessories.

Founded in 1958 by engineer Miles “Lowell” Edwards, the company helped pioneer artificial heart valves and has played a significant role in the development of transcatheter valve replacement.